Drug Profile
NGX 267
Alternative Names: AF 267B; NGX-267Latest Information Update: 06 Nov 2023
Price :
$50
*
At a glance
- Originator Horizon Pharma; Life Science Research Israel
- Developer Raptor Pharmaceutical Corp
- Class Antidementias; Nootropics; Piperidines; Small molecules; Spiro compounds; Thiazolidines
- Mechanism of Action Amyloid beta-protein inhibitors; Muscarinic M1 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Alzheimer's disease; Cognition disorders; Xerostomia
Most Recent Events
- 02 May 2019 Horizon Pharma is now called Horizon Therapeutics plc
- 03 Nov 2009 Discontinued - Phase-I for Alzheimer's disease in USA (PO)
- 03 Nov 2009 Discontinued - Phase-I for Cognition disorders in Belgium (PO)